December 7th 2015
Phase Ib/II research has shown promise for adoptive cellular therapy combined with ipilimumab in patients with advanced sarcomas.
December 4th 2015
Combining the investigational antibody TRC105 with Votrient showed promising antitumor activity in patients with soft tissue sarcoma.
November 3rd 2015
Researchers from United States and Ireland have formed a partnership to advance nanoparticle-based delivery systems that would not only drive sustained-release of cytotoxic agents, but also could improve penetration of these treatments within the tumor and allow them to continue working for days or weeks.
February 21st 2015
Although treatments and cure rates have increased significantly over the past 60 years for patients with Hodgkin lymphoma, it is crucial that practitioners stay up-to-date on research that can affect outcomes for their patients with this uncommon form of cancer.
October 27th 2014
The FDA has granted a breakthrough therapy designation to pembrolizumab (Keytruda), an anti-PD-1 therapy, for the treatment of patients with non-small cell lung cancer (NSCLC) who are EGFR mutation- or ALK rearrangement-negative and whose disease has progressed on or following platinum-based chemotherapy.
September 2nd 2014
One of the first studies to prospectively examine women's breast surgery preferences has revealed that newly diagnosed women with breast cancer who decide to undergo contralateral prophylactic mastectomy (CPM), may be making this decision as result of high anxiety and fear of recurrence, rather than relying on evidence-based information.
June 3rd 2014
Long-term follow-up results demonstrated nearly doubled median OS with the combination of ipilimumab and nivolumab compared with either agent alone.
June 2nd 2014
A joint analysis of two phase III trials involving a total of 4690 premenopausal women with hormone-receptorâ€“positive (HR+) breast cancer demonstrated that adjuvant use of the aromatase inhibitor (AI), exemestane, reduced relative risk of developing subsequent invasive cancer by 28% compared with tamoxifen when both agents were combined with ovarian function suppression (OFS).
June 1st 2014
MPDL3280A reduced tumors in 43% of patients with previously treated PD-L1-positive metastatic bladder cancer, resulting in the first breakthrough therapy designation from the FDA for a treatment in this setting.
May 31st 2014
For patients with less than a year to live, the discontinuation of statins may increase the median time-to-death and improve quality of life.
March 17th 2014
Increasing efficacy with immunotherapies in some cancers led to the strategy being deemed Breakthrough of the Year by Science magazine in 2013
January 28th 2014
A vast, pooled retrospective analysis has demonstrated that the use of ASIs may significantly improve survival outcomes in patients with mRCC.
January 14th 2014
Data from an interim analysis of an ongoing phase II study suggest that patients with carcinoid and pituitary NETs, who have been traditionally chemo-resistant, may obtain "extraordinary responses" with capecitabine and temozolomide.
November 21st 2011
In the United States, the incidence of lung cancer has increased in those aged >74 years and will likely continue to rise.
November 14th 2011
A conversation with Denise R. Aberle, MD, on the National Lung Screening Trial (NLST) at the 12th International Lung Cancer Congress.
July 13th 2011
Although researchers know that estrogen plays a role in most cases of breast cancer, they don't fully understand how.
June 11th 2011
Immunotherapies made headlines in oncology last month when the Centers for Medicare & Medicaid Services (CMS) decided that the anticancer vaccine sipuleucel-T (Provenge) will be a payable expense for prostate cancer.
June 10th 2011
Therapies that target bone metastases have been developed for more than a decade.
May 18th 2011
A large-scale study of HPV testing and Pap smear for cervical cancer screening confirms that women can safely extend screening intervals from 1 to 3 years.